Clinical trial · Interventional
Phase I Study of KRN330 Monoclonal Antibody in Patients With Colorectal Cancer
NCT00575562CI-TRIAL-00076567completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The primary objective of this study is to assess the safety and tolerability of KRN330 in patients with relapsed or refractory advanced or metastatic colorectal cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| KRN330 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- The primary objective of this study is to assess the safety and tolerability of KRN330 in patients with relapsed or refractory advanced or metastatic colorectal cancer.
- timeFrame
- For up to12 weeks
Secondary outcomes (1)
- measure
- The secondary objectives are to determine the degree of immunogenicity, gain information on the pharmacokinetic profile, assess the anti-tumor effects of KRN330 and determine the maximum tolerated dose (MTD).
- timeFrame
- For up to12 weeks
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Have histologically confirmed colorectal cancer that is advanced or metastatic with measurable or assessable disease. 2. Are not candidates for a surgically curative procedure. 3. Have progressed despite, are intolerant of, or are not appropriate for current therapies. Exclusion Criteria: 1. Have an active, uncontrolled infection. 2. Have known or suspected cerebral metastasis. 3. Have had a myocardial infarction (MI) or cerebrovascular accident (CVA) within the last 6 months; or meet the criteria for AHA class III or IV congestive heart failure (CHF). 4. Have any significant concurrent disease or illness that would interfere with the interpretation of study results. 5. Pregnant or breastfeeding women and male or female patients who do not agree to use effective contraceptive method(s) during the study. \-
References
Publications (0)
Data not yet available
No reference posted for this study.